10-QPeriod: Q3 FY2014

AbbVie Inc. Quarterly Report for Q3 Ended Sep 30, 2014

Filed November 7, 2014For Securities:ABBV

Summary

AbbVie Inc. reported solid financial results for the nine months ended September 30, 2014, with net sales increasing by 6% to $14.508 billion. This growth was primarily driven by the strong performance of HUMIRA, which saw a 21% increase in sales year-to-date, and contributions from other key products like Creon and Duodopa. Despite this revenue growth, net earnings for the period decreased to $2.584 billion from $3.000 billion in the prior year, partly due to increased operating costs, including higher selling, general, and administrative (SG&A) expenses and research and development (R&D) investments. A significant event during the quarter was the termination of the proposed acquisition of Shire plc. This termination resulted in a $1.635 billion break fee paid in October 2014, which will be recorded as SG&A expense in the fourth quarter. The company also continued its strategic focus on pipeline advancement and product lifecycle management, including investments in R&D for new therapies in areas like immunology and oncology. AbbVie also returned capital to shareholders through dividends and share repurchases, demonstrating a commitment to shareholder value.

Financial Highlights

51 data points
Beta

Revenue

$5.02B

78.2% Gross Margin

Net Income

$506.00M

10.1% Net Margin

EPS (Diluted)

$0.31

Total Assets

$28.45B

Cash & Equivalents

$7.72B

Free Cash Flow

$1.61B

Financial Statements
Beta
Revenue$5.02B
Cost of Revenue$1.09B
Gross Profit$3.92B
SG&A Expenses$1.59B
Operating Expenses$4.06B
Operating Income$960.00M
Interest Expense$148.00M
Net Income$506.00M
EPS (Basic)$0.32
EPS (Diluted)$0.31
Shares Outstanding (Basic)1.59B
Shares Outstanding (Diluted)1.61B

Key Highlights

  • 1AbbVie reported a 6% increase in net sales for the first nine months of 2014, reaching $14.508 billion, driven by strong HUMIRA performance and growth in other key products.
  • 2HUMIRA sales demonstrated robust growth, increasing by 21% year-to-date on a constant currency basis, highlighting its continued market strength and expansion into new indications.
  • 3The proposed acquisition of Shire plc was terminated in October 2014, resulting in a significant $1.635 billion break fee to be recognized in the fourth quarter.
  • 4Operating expenses increased, with SG&A up 12% and R&D up 18% year-to-date, reflecting investments in pipeline development, new product launches, and separation-related costs.
  • 5Net earnings decreased to $2.584 billion for the nine months ended September 30, 2014, compared to $3.000 billion in the prior year, impacted by increased operating costs and the Shire termination-related expenses.
  • 6The company generated $4.127 billion in cash flow from operations year-to-date, while actively returning capital to shareholders through $1.987 billion in dividend payments and $250 million in share repurchases.
  • 7AbbVie continued to invest in its R&D pipeline, with significant progress noted in areas such as an interferon-free combination therapy for Hepatitis C and clinical trials for oncology treatments.

Frequently Asked Questions

The primary driver of AbbVie's net sales growth was the continued strong performance of its flagship product, HUMIRA. HUMIRA sales increased by 21% year-to-date on a constant currency basis, benefiting from market growth, increased market share, higher pricing, and the approval of new indications.

The proposed acquisition of Shire plc was terminated in October 2014. AbbVie paid a break fee of $1.635 billion to Shire, which is expected to be tax-deductible and will be recorded as SG&A expense in the fourth quarter of 2014. This termination also led to the cancellation of associated financing agreements.

Operating expenses increased significantly. Selling, General, and Administrative (SG&A) expenses rose by 12% year-to-date, driven by separation-related costs, increased marketing support for new products and HUMIRA indications, and a $129 million charge related to the Branded Prescription Drug Fee. Research and Development (R&D) expenses increased by 18% year-to-date due to increased funding for mid- and late-stage pipeline assets and continued pursuit of HUMIRA indications. Acquired in-process R&D also increased due to new collaboration agreements.

AbbVie's strategy focuses on maximizing its existing portfolio through new indications and geographic expansion, particularly for HUMIRA. Concurrently, it aims to advance its pipeline of new medicines, with over 20 compounds in Phase 2 or 3 development across key therapeutic areas like immunology, oncology, and virology. The company also engages in strategic collaborations and acquisitions to enhance its product offerings and R&D capabilities.